Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease?

BACKGROUNDAdalimumab (ADA) is a subcutaneous anti-tumour necrosis factor (anti-TNF) agent, effective in inducing and maintaining remission in Crohn’s disease (CD). Unlike Infliximab (IFX), ADA dosing is not weight adjusted and dose frequency is based on clinical response. AIMTo determine whether obe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of gastroenterology & hepatology 2013-05, Vol.25 (5), p.543-549
Hauptverfasser:	Bhalme, Mahesh, Sharma, Abhishek, Keld, Richard, Willert, Robert, Campbell, Simon
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Adolescent Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - therapeutic use Body Mass Index Body Weight - physiology Crohn Disease - complications Crohn Disease - drug therapy Dose-Response Relationship, Drug Drug Administration Schedule Drug Tolerance - physiology Female Gastrointestinal Agents - administration & dosage Gastrointestinal Agents - therapeutic use Humans Infliximab Kaplan-Meier Estimate Male Middle Aged Obesity - complications Obesity - physiopathology Retrospective Studies Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BACKGROUNDAdalimumab (ADA) is a subcutaneous anti-tumour necrosis factor (anti-TNF) agent, effective in inducing and maintaining remission in Crohn’s disease (CD). Unlike Infliximab (IFX), ADA dosing is not weight adjusted and dose frequency is based on clinical response. AIMTo determine whether obesity is a risk factor for early loss of response (LOR) to anti-TNF treatment and whether weight-adjusted anti-TNF treatment is favourable. MATERIALS AND METHODSA hospital database of CD patients receiving anti-TNF treatment was analyzed retrospectively. The relationship between time to LOR and BMI was examined by Kaplan–Meier (KM) survival curves and a Cox proportional hazards model. RESULTSADA patientsOf the 54 patients (46 BMI
ISSN:	0954-691X 1473-5687
DOI:	10.1097/MEG.0b013e32835d1f15